9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

Atezolizumab and Bevacizumab in Rare Solid Tumors

Estimated reading time: < 1 min

Condition

Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs

Estimated Enrollment: 160

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 2016-0861|NCI-2017-00501

Study First Received: February 22, 2017

Last Updated: April 19, 2017

Estimated Primary Completion Date: March 2021

Primary Outcome Measures:

Overall Response Rate of Atezolizumab in Combination with Bevacizumab|Adverse Events of Atezolizumab in Combination with Bevacizumab

Sponsors and Collaborators:

M.D. Anderson Cancer Center|Genentech, Inc.

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT03074513

Was this article helpful?
Views: 13